Chromophobe renal cell carcinoma: A review of an uncommon entity

International Journal of Urology

Volumn 19, Issue 10, 2012, Pages 894-900

  Vera Badillo, Francisco Emilio ^a   Conde, Esther ^a   Duran, Ignacio ^a,b  

^a Madrid Sanchinarro University Hospital   (Spain)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

Author keywords

Chromophobe renal cell carcinoma; Mammalian target of rapamycin inhibitors; Metastatic renal cell carcinoma; Renal cell carcinoma; Tyrosine kinase inhibitors

Indexed keywords

CYTOKERATIN 7; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRONE; FERRIC HYDROXIDE; IMATINIB; INTERFERON; MESSENGER RNA; NILOTINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

AGE DISTRIBUTION; ALLELE; BIRT HOGG DUBE SYNDROME; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 17; CHROMOSOME ABERRATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; FAMILIAL DISEASE; GENE; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LUNG CYST; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOCYTOMA; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SURVIVAL RATE; TUMOR VOLUME;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM STAGING; PROGNOSIS;

EID: 84866773557     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03079.x     Document Type: Review

References (66)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60: 277-300.
2. Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat. Rev. Urol. 2010; 7: 327-38.
3. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J. Urol. 2005; 23: 202-12.
4. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 1996; 335: 865-75.
5. Kovacs G, Akhtar M, Beckwith BJ etal. The Heidelberg classification of renal cell tumours. J. Pathol. 1997; 183: 131-3.
6. Eble J, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon, 2004.
7. Yang JC, Haworth L, Sherry RM etal. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003; 349: 427-34.
8. Escudier B, Eisen T, Stadler WM etal. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 125-34.
9. Motzer RJ, Hutson TE, Tomczak P etal. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 115-24.
10. Sternberg CN, Davis ID, Mardiak J etal. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 2010; 28: 1061-8.
11. Rini BI, Wilding G, Hudes G etal. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2009; 27: 4462-8.
12. Escudier B, Bellmunt J, Negrier S etal. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 2010; 28: 2144-50.
13. Rini BI, Halabi S, Rosenberg JE etal. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 2010; 28: 2137-43.
14. Hudes G, Carducci M, Tomczak P etal. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 2271-81.
15. Motzer RJ, Escudier B, Oudard S etal. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
16. Amin MB, Paner GP, Alvarado-Cabrero I etal. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am. J. Surg. Pathol. 2008; 32: 1822-34.
17. Papanikolaou PN, Churchill R, Wahlbeck K, Ioannidis JP. Safety reporting in randomized trials of mental health interventions. Am. J. Psychiatry 2004; 161: 1692-7.
18. Prasad SR, Humphrey PA, Catena JR etal. Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics 2006; 26: 1795-806; discussion 1806-10.
19. Stec R, Grala B, Maczewski M, Bodnar L, Szczylik C. Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease. J. Exp. Clin. Cancer Res. 2009; 28: 134.
20. Thoenes W, Storkel S, Rumpelt HJ, Moll R, Baum HP, Werner S. Chromophobe cell renal carcinoma and its variants - a report on 32 cases. J. Pathol. 1988; 155: 277-87.
21. Thoenes W, Storkel S, Rumpelt HJ. Human chromophobe cell renal carcinoma. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1985; 48: 207-17.
22. Skinnider BF, Folpe AL, Hennigar RA etal. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am. J. Surg. Pathol. 2005; 29: 747-54.
23. Martignoni G, Pea M, Chilosi M etal. Parvalbumin is constantly expressed in chromophobe renal carcinoma. Mod. Pathol. 2001; 14: 760-7.
24. Van der Kwast T, Perez-Ordonez B. Renal oncocytoma, yet another tumour that does not fit in the dualistic benign/malignant paradigm? J. Clin. Pathol. 2007; 60: 585-6.
25. Koeman JM, Russell RC, Tan MH etal. Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated EGLN2-mediated [corrected] oxygen-sensing response. PLoS Genet. 2008; 4: e1000176.
26. Kawaguchi S, Fernandes KA, Finelli A, Robinette M, Fleshner N, Jewett MA. Most renal oncocytomas appear to grow: observations of tumor kinetics with active surveillance. J. Urol. 2011; 186: 1218-22.
27. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J. Clin. Oncol. 1999; 17: 523-8.
28. Shuch B, Bratslavsky G, Linehan WM, Srinivasan R. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist 2012; 17: 46-54.
29. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011; 61: 212-36.
30. Zini L, Leroy X, Lemaitre L etal. Tumour necrosis in chromophobe renal cell carcinoma: clinical data to distinguish aggressive variants. Eur. J. Surg. Oncol. 2008; 34: 687-91.
31. Kovacs G, Soudah B, Hoene E. Binucleated cells in a human renal cell carcinoma with 34 chromosomes. Cancer Genet. Cytogenet. 1988; 31: 211-15.
32. Furge KA, Lucas KA, Takahashi M etal. Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res. 2004; 64: 4117-21.
33. Yusenko MV. Molecular pathology of chromophobe renal cell carcinoma: a review. Int. J. Urol. 2010; 17: 592-600.
34. Zbar B, Alvord WG, Glenn G etal. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol. Biomarkers Prev. 2002; 11: 393-400.
35. Pavlovich CP, Walther MM, Eyler RA etal. Renal tumors in the Birt-Hogg-Dube syndrome. Am. J. Surg. Pathol. 2002; 26: 1542-52.
36. Singer EA, Bratslavsky G, Linehan WM, Srinivasan R. Targeted therapies for non-clear renal cell carcinoma. Target Oncol. 2010; 5: 119-29.
37. Baba M, Hong SB, Sharma N etal. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc. Natl. Acad. Sci. U.S.A. 2006; 103: 15552-7.
38. Chen J, Futami K, Petillo D etal. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS ONE 2008; 3: e3581.
39. Hasumi Y, Baba M, Ajima R etal. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc. Natl. Acad. Sci. U.S.A. 2009; 106: 18722-7.
40. Nagy A, Zoubakov D, Stupar Z, Kovacs G. Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma. Int. J. Cancer 2004; 109: 472-5.
41. Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003; 22: 847-52.
42. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int. 2004; 93: 297-302.
43. Linehan WM, Rini BI, Yang J. DeVita, Hellmand, and Rosenberg's cancer: principles and practice of oncology. In: DeVita V (ed.). Cancer of the Kidney, 9th edn. Lippincott Williams & Wilkins, Philadelphia, 2011; 1161-82.
44. Toro JR, Glenn G, Duray P etal. Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch. Dermatol. 1999; 135: 1195-202.
45. Jinzaki M, Kuribayashi S. Dynamic contrast-enhanced CT of renal cell carcinoma for evaluation of tumor vascularity: analysis of single-phase or multiphase scanning. AJR Am. J. Roentgenol. 2007; 188: W569; author reply W570.
46. Kim JK, Kim TK, Ahn HJ, Kim CS, Kim KR, Cho KS. Differentiation of subtypes of renal cell carcinoma on helical CT scans. AJR Am. J. Roentgenol. 2002; 178: 1499-506.
47. Sun MR, Ngo L, Genega EM etal. Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes - correlation with pathologic findings. Radiology 2009; 250: 793-802.
48. Crotty TB, Farrow GM, Lieber MM. Chromophobe cell renal carcinoma: clinicopathological features of 50 cases. J. Urol. 1995; 154: 964-7.
49. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol. 2003; 27: 612-24.
50. Amin MB, Tamboli P, Javidan J etal. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am. J. Surg. Pathol. 2002; 26: 281-91.
51. Lee WK, Byun SS, Kim HH etal. Characteristics and prognosis of chromophobe non-metastatic renal cell carcinoma: a multicenter study. Int. J. Urol. 2010; 17: 898-904.
52. Klatte T, Han KR, Said JW etal. Pathobiology and prognosis of chromophobe renal cell carcinoma. Urol. Oncol. 2008; 26: 604-9.
53. Capitanio U, Cloutier V, Zini L etal. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJU Int. 2009; 103: 1496-500.
54. Patard JJ, Leray E, Rioux-Leclercq N etal. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J. Clin. Oncol. 2005; 23: 2763-71.
55. Renshaw AA, Richie JP. Subtypes of renal cell carcinoma. Different onset and sites of metastatic disease. Am. J. Clin. Pathol. 1999; 111: 539-43.
56. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol. 2002; 20: 2376-81.
57. Rini BI, Halabi S, Rosenberg JE etal. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 2008; 26: 5422-8.
58. Tan MH, Wong CF, Tan HL etal. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer 2010; 10: 196.
59. Schuetz AN, Yin-Goen Q, Amin MB etal. Molecular classification of renal tumors by gene expression profiling. J. Mol. Diagn. 2005; 7: 206-18.
60. Zardavas D, Meisel A, Samaras P etal. Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer. Case Rep. Oncol. 2011; 4: 16-18.
61. Paule B, Brion N. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy. Anticancer Res. 2011; 31: 331-3.
62. Larkin JM, Fisher RA, Pickering LM etal. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. J. Clin. Oncol. 2011; 29: e241-2.
63. Procopio G, Verzoni E, Bajetta E. Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma. Med. Oncol. 2010; 27: 1267-8.
64. Stadler WM, Figlin RA, McDermott DF etal. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116: 1272-80.
65. Choueiri TK, Plantade A, Elson P etal. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 2008; 26: 127-31.
66. Gore ME, Szczylik C, Porta C etal. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009; 10: 757-63.